Hong Kong-listed Keymed Biosciences' gastric cancer drug meets late-stage trial goals

• The drug met its primary endpoint of overall survival for third-line or later treatment and a key secondary endpoint for second-line or later treatment in advanced/metastatic gastric cancer patients
• The therapy failed to achieve statistical significance in progression-free survival, one of its other primary goals, though it showed an improving trend
• Based on trial results, AstraZeneca estimates peak sales for the product will reach $3.0 billion to $5.0 billion

Summary: Keymed Biosciences' Gastric Cancer Drug Achieves Late-Stage Trial Success

Hong Kong-listed Keymed Biosciences announced on July 28 that its late-stage clinical trial for sonesitatug vedotin, a gastric cancer treatment, achieved positive topline results. The therapy targets advanced or metastatic gastric cancer and is being developed through KYM Biosciences, a joint venture between Keymed and Lepu Biopharma, in collaboration with AstraZeneca.

Key Trial Results

The global Phase III trial demonstrated "highly clinically meaningful improvement" in overall survival compared to standard chemotherapy. The drug successfully met:

• Primary endpoint of overall survival for third-line or later treatment
• Key secondary endpoint of overall survival for second-line or later treatment

However, the therapy did not achieve statistical significance in progression-free survival (time without disease worsening), though it showed an improving trend. Both companies confirmed the drug was well-tolerated with no new safety concerns.

Market Implications

Based on these positive results, AstraZeneca has estimated peak sales between $3.0 billion and $5.0 billion for the product, signaling strong commercial potential in the oncology market.

Sector Impact

This development is significant for the gastric cancer treatment landscape, particularly for patients who have exhausted multiple treatment lines. The collaboration between Asian biotech firms and a major pharmaceutical player like AstraZeneca demonstrates the growing importance of international partnerships in drug development. The estimated multi-billion-dollar peak sales forecast suggests substantial market opportunity in addressing this unmet medical need, potentially benefiting all three companies involved in the joint venture.